1.	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000574159, CHUL-BIO-COLON, INCA-RECF0356, RECF0356, NCT00559676
2.	Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 21 Sponsor: Other Protocol IDs: PK01/16/08, NCT00808184
3.	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CPT_08_001, NCT01271582
4.	Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 21 at relapse Sponsor: NCI Protocol IDs: POG-9410, POG-SIMAL-8
5.	Phase II/III Randomized Study of Fluorouracil/Leucovorin with vs without Oxaliplatin for Inoperable Metastatic Colorectal Cancer (Summary Last Modified 03/98) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: FRE-DEB95-OXA-01, EU-96023
6.	Master Protocol to Compare MTX/5-FU vs CACP/5-FU vs Phase II Agent for Squamous Cell Cancer of the Head and Neck (Summary last modified 06/97) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-8223/24/25, SWOG-8224, SWOG-8225
7.	Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 65 Sponsor: Protocol IDs: WCCC-CO-7711R, NCI-D80-048-183
8.	Phase II/III Evaluation of Intraoperative Radiotherapy and Adjuvant Chemotherapy with CAM (CTX/ADR/MTX) for Nonmetastatic Soft Tissue Retroperitoneal Sarcoma Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 10 to 65 Sponsor: NCI Protocol IDs: NCI-80-C-45, NCI-SB-S9, NCI-T83-1103N, T83-1103
9.	Phase II/III Adjuvant ADR/CTX Followed by High-Dose MTX vs ADR/CTX Alone, with Radiotherapy in Selected Cases, for Histologic Grade II/III Soft Tissue Sarcoma of an Extremity Phase: Phase III, Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: Protocol IDs: NCI-82-C-100
10.	Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: NCI-D82-013-686
11.	Phase II-III Chemotherapy with High-Dose Methotrexate and Adriamycin plus Radiotherapy for Primary and Metastatic Osteogenic Sarcoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 20 and under Sponsor: Protocol IDs: CHOP-204
12.	Phase II Chemotherapy with MTX/CF, Aminopterin or M-BACOD plus CTX or BCG Immunotherapy for Advanced non-Hodgkin's Lymphoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 25 to 65 Sponsor: Protocol IDs: DFCI-75116
13.	Phase II/III Induction Chemotherapy with CACP/BLEO/MTX/CF vs CACP/5-FU for Stage II/III/IV, Previously Untreated Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 09/88) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-83084, NCI-T84-0282D, T84-0282
14.	Phase II/III Study of Induction with ARA-C/ADR plus Intensive Consolidation with Various Combinations of ADR, ARA-C, and AMSA for AML Phase: Phase III, Phase II Type: Treatment Status: Closed Age: physiologic 70 and under Sponsor: NCI Protocol IDs: RPMI-PPC-744, NCI-T83-0960D
15.	Phase II/III Pilot Combination Chemotherapy with ARA-C/VP-16/IPP plus Mesna plus Intrathecal MTX in Pediatric Patients with Recurrent Nonlymphoblastic Lymphoma (Summary Last Modified 07/90) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 18 Sponsor: NCI Protocol IDs: NCI-85-C-62, NCI-T85-0096N, T85-0096
16.	Phase II/III Randomized Study of Standard-Dose vs High-Dose MTX Followed by Induction and Continuation for Patients with ALL or AUL Phase: Phase III, Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: DFCI-81001, NCI-D82-018-0400, D82-018-0400
17.	Phase II/III Randomized Trial of Chemotherapy with FAMTX (5-FU/ADR/MTX) vs FAM (5-FU/ADR/MITO) in Patients with Metastatic Gastric Cancer (Summary Last Modified 04/88) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 70 and under Sponsor: Protocol IDs: EORTC-40851
18.	Phase II/III Study of BU/CY with vs without TBI as Preparative Regimens for Autologous Marrow Transplantation in Patients with Acute Nonlymphoblastic Leukemia (Summary Last Modified 01/90) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 55 and under Sponsor: Protocol IDs: FHCRC-458, NCI-V89-0268
19.	Phase II/III Chemotherapy with IPP plus Mesna/MTX/CF/ADR/CDDP with Surgery for Patients with Osteosarcoma or Fibrosarcoma of the Bone Who Have Had No Prior Chemotherapy (Summary Last Modified 05/90) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 25 Sponsor: NCI Protocol IDs: SJCRH-OS-86, NCI-T86-0086D, T86-0086
20.	Phase II/III Randomized Comparison of Up-Front Alternating Chemotherapy vs Up-Front Intensive 6-MP/MTX for Poor Prognosis Childhood ALL Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 1 to 20 Sponsor: NCI Protocol IDs: POG-8698
21.	Phase II/III Pilot Study of Induction and Intensification Chemotherapy with VP-16, ARA-C, DNR, 5-AZ, and m-AMSA, Using "Modelled" Plasma Drug Concentrations of VP-16 and ARA-C, in Children with Acute Nonlymphocytic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 21 Sponsor: NCI Protocol IDs: SJCRH-AML-87, NCI-T86-0203D, T86-0203
22.	Phase II/III Induction Chemotherapy with IPP in Patients with Untreated Metastatic or Nonresectable Primary Osteosarcoma or Recurrent Osteosarcoma (Summary Last Modified 04/97) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: under 31 Sponsor: NCI Protocol IDs: POG-8759
23.	Phase II/III Randomized Study of MP/MTX vs DCF/MP/MTX in Patients with Relapsed T-ALL or T-NHL Who Achieve Second Remission Following Induction with PVDA (PRED/VCR/DNR/ASP) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8862
24.	Phase II/III Randomized Comparison of VP-16/AMSA vs VP-16/AMSA/AZC in Children with Refractory ANLL (Summary Last Modified 10/91) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: POG-8820
25.	Phase III Treatment of Residual or Unresectable Carcinoma of the Rectum or Rectosigmoid or Localized Pelvic Recurrence Following Resection of Primary Colorectal Cancer: External Beam Radiotherapy plus 5-FU/Leucovorin with Intraoperative Electron Boost vs External Beam Photon Boost (Summary Last Modified 03/90) Phase: Phase III, Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: RTOG-8820, RTOG-88-20